D
Dariusz M. Kowalski
Researcher at Curie Institute
Publications - 161
Citations - 12935
Dariusz M. Kowalski is an academic researcher from Curie Institute. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 25, co-authored 129 publications receiving 7930 citations.
Papers
More filters
Journal ArticleDOI
Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407
Julien Mazieres,Dariusz M. Kowalski,Alexander Luft,David Vicente,Ali Tafreshi,Mahmut Gumus,Konstantin Laktionov,Barbara Hermes,Irfan Cicin,J. Rodríguez-Cid,Jonathan Wilson,Terufumi Kato,Rodryg Ramlau,Silvia Novello,Sreekanth Reddy,Bilal Piperdi,Xiaoyun Nicole Li,Thomas Burke,Luis Paz-Ares +18 more
Journal ArticleDOI
Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial
Antonio Passaro,Konstantin Laktionov,A. Poltoratskiy,I. Egorova,Maximilian Hochmair,Maria Rita Migliorino,Giulio Metro,Maya Gottfried,D. Tsoi,Gyula Ostoros,Simona Rizzato,G.Z. Mukhametshina,Michael Schumacher,Silvia Novello,Rafal Dziadziuszko,W. Tang,L. Clementi,Agnieszka Cseh,Dariusz M. Kowalski,F. De Marinis +19 more
Journal ArticleDOI
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC.
Tony Mok,Gilberto Lopes,Byoung Chul Cho,Dariusz M. Kowalski,Kohei Kasahara,Y. Wu,Gilberto de Castro,Hande Turna,Razvan Cristescu,Deepti Aurora-Garg,Andrey Loboda,Jared Lunceford,J. Kobie,Mark Ayers,M. Catherine Pietanza,Bilal Piperdi,R. S. Herbst +16 more
TL;DR: In this article , the authors evaluated whether tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in patients with PD-L1-positive (tumor proportion score ≥ 1%) advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations in the phase III KEYNOTE-042 trial.
Journal ArticleDOI
Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors
TL;DR: A retrospective analysis based on registry data included 89 patients diagnosed with primary tracheal cancer at the National Research Institute of Oncology in Warsaw, Poland, between January 2000 and December 2016 and found a significant difference in overall survival depending on the T, N, M categories in the entire group.
Journal Article
[Gefitinib in patients with advanced non-small-cell lung cancer].
Magdalena Knetki-Wróblewska,Dariusz M. Kowalski,Katarzyna Zajda,Adam Pluzanski,Pawel Badurak,Anna Janowicz-Żebrowska,Piotr Jaśkiewicz,Maciej Krzakowski +7 more
TL;DR: The results confirm the literature data on the efficacy and safety profile of gefitinib in the treatment of patients with the diagnosis of advanced NSCLC and activating mutation in the EGFR gene.